Scientific Program

This was the program of the ESVONC congress in Hofheim-am-Taunus:

We kicked off with a precongress Resident Workshop on Wednesday 22 May.

For the main congress, we had 3 half-day Themed Sessions, where the next subjects were discussed in-depth by experts in that field:

Thursday 23 May: Histiocytic proliferative diseases,
Friday 24 May : Inflammation and cancer,
Saturday 25 May: Pathologist-Clinician interaction

On Saturday 25 May ESVONC organized its very first Symposium for Veterinary Nurses and Technicians: for the program, see on this link.

There were 2 social events:

the Welcome Reception on Thursday evening 23 May : on a boat on the river Main, showing Frankfurt evening skyline
the Gala Dinner on Friday evening 24 May : eating, drinking and partying at the lovely Palmengarten venue.

-----------------------------------------------------

Programs in detail

This program is RACE approved: click to verify

Program Number: 36457, Provider Number: 1385, CE Hours:Vet: 11.50, Vet Tech: 4.25, Subject Matter Categories:Medical Program, Delivery Methods:Seminar/Lecture

Resident's workshop - Wednesday 22 May 2019

time	title	speaker
Radiation therapy and photodynamic therapy
15:30-16:15	Radiation biology – fundamental concepts for medical oncologists	dr. Carla Rohrer
16:15-17:00	Techniques in radiation therapy: 3DCRT, IMRT and beyond	dr. Carla Rohrer
17:00-17:30	Coffee break
17:30-18:15	Brachytherapy and plesiotherapy in veterinary oncology	dr. Jérôme Benoit
18:15-19:00	Photodynamic therapy in veterinary oncology: principles and applications	dr. Julia Buchholz

Main Program - Thursday 23 May 2019

time	title	speaker
*08h00-09h00*	*Registration opens*
	Themed session: Histiocytic proliferative diseases
09:00-09:45	Key note lecture: Current understanding of histiocytic proliferative diseases	dr. Jérôme Abadie, Nantes
09:45-10:30	Pathophysiological and genetic mechanisms associated with histiocytic malignancies	dr. Benoit Hédan, Nantes
10:30-11:00	coffee break
11:00-11:12	Periarticular histiocytic sarcoma (PAHS) – Epidemiology, clinical characteristics and prognosis in 70 dogs	dr. Julia Gedon
11:14-11:28	Comparison of computed tomographic (CT) appearance of pulmonary involvement in localized and systemic histiocytic sarcoma in dogs	dr. Jan Wennemuth
11:30-12:15	Clinical management of canine systemic histiocytic sarcoma: past, present and what is up on the horizon?	dr. Jane Dobson, Cambridge
12:15-12:45	Round table discussion	all speakers
12:45-13:00	Welcome ESVONC to Frankfurt! – what to see and what to do!	dr. Martin Kessler
13:00-14:15	Lunch
	Resident abstracts
14:15-14:27	Adjuvant dose-intense versus metronomic chemotherapy for dogs with metastatic splenic hemangiosarcoma: a multi-institutional retrospective study	dr. Carmit Chalfon
14:29-14:41	Is radiation therapy a useful treatment option for meningoencephalomyelitis of unknown origin in dogs?	dr. Maximilian Körner
14:43-14:55	DNA double-strand breaks quantification in U87 cell-line exposed to 165Holmium, combined with ionizing radiation	dr. Pauline Denoeux
14:55-15:07	Low dose metronomic cyclophosphamide as adjuvant treatment in feline mammary carcinomas – A preliminary evaluation	dr. Gonçalo Petrucci
15:10-15:40	Coffee break
	General abstracts
15:40-15:52	Evaluation of a double deleted oncolytic Vaccinia virus encoding FCU1 protein in dogs diagnosed with malignant solid tumors	dr. Jérémy Béguin
15:55-16:07	Canine anal sac adenocarcinoma with lymph node metastases treated with anal sacculectomy and lymphadenectomy: is there a need for a new staging system?	dr. Jean-Benoit Tanis
16:09-16:21	Definitive radiation therapy for dogs with oral papillary squamous cell carcinoma.	dr. Francine van der Steen
16:30-17:30	ESVONC Annual General Meeting (ESVONC members)
19:00-21:00	Welcome reception on the river Main – see Frankfurt’s skyline by night

Main Program - Friday 24 May 2019

time	title	speaker
	Themed session: Inflammation and cancer
9:00-9:45	Inflammation in cancer initiation and maintenance	prof. David Argyle, Edinburgh
9:45-10:30	Inflammation in tumor progression and metastasis	prof. Florian Greten, Frankfurt
10:30-11:00	Coffee break
11:00-11:30	The role of Cyclooxygenase-2 in cancer stem cell survival and repopulation during anticancer therapy	dr. Lisa Pang, Edinburgh
11:30-12:00	COX-2–independent anticarcinogenic effects of COX-Inhibitors	prof. Sabine Grösch, Frankfurt
12:00-12:30	The use of COX-2 inhibitors in treating cancer: what’s the evidence?	prof. David Argyle, Edinburgh
12:30-13:00	Panel discussion
13:00-14:15	Poster session, and invited snack lunch in the industrial exhibition
	General abstracts
14:15-14:27	Expression of HIF-1 alpha and hypoxia-related markers correlate with prognosis in canine appendicular osteosarcoma	dr. Cecilia Gola
14:29-14:41	Non-Injection site soft tissue sarcoma in cats: Outcome following adjuvant radiotherapy	dr. Alenka Lavra Zajc
14:43-14:55	Using the dog’s definitive-intent radiotherapy protocol for sinonasal carcinomas in cats: a multicenter retrospective assessment	dr. Katerina Stiborova
14:57-15:09	High-Resolution Transcriptome Analysis of Feline Mammary Carcinomas and derived cell lines	dr. Joé-Luis Granados Soler
*15:20-15:50*	*Coffee break*
15:50-16:02	Outcomes of canine subcutaneous mast cell tumours treated with adjunctive radiation therapy	dr. Begoña Pons Gil
16:02-16:14	Radiotherapy Outcomes in Dogs with Solitary Plasma Cell Tumors: 29 Cases	dr. Blaise Burke
16:14-16:26	Outcome of canine high-risk cutaneous mast cell tumours treated with adjuvant radiation therapy alone or combined with chemotherapy	dr. Onne-Marju Russak
16:26-16:38	Malignant melanoma of the nasal planum in cats - A report of 6 cases	dr. Amalia Reck
16:38-16:50	Discovery of chromosomal amplifications in canine oral melanoma as a new prognostic factor	dr. Anaïs Prouteau
16:50-17:02	Controlled, Randomized Study of Intratumoral Tigilanol Tiglate (EBC-46) for Treatment of Canine Mast Cell Tumors	dr. Johannes Chad
*19:30-??:??*	Gala Dinner in Gesellschaftshaus Palmengarten

Main program - Saturday 25 May

time	title	speaker
8:00-9:00	Guided tour through Hofheim Veterinary Hospital (one of the largest private veterinary hospitals in Europe)
	Themed session: pathologist – clinician interaction
9:15-10:00	Key note lecture by chair: How do you get what you need? Problems and pitfalls in the pathologist – clinician interaction	prof. Marije Risselada, Purdue
10:00-10:45	Determining resection margins as a pathologist – clean but close or too close to be clean?	dr. Annika Herrmann, Bristol
10:45-11:15	Coffee break - visiting the poster exhibition
11:15-12:00	On the cutting edge: a surgical oncologist’s perspective on resection margins	prof. Marije Risselada, Purdue
12:00-12:30	Mitotic index, Ki67 – preanalytic complications, analytic variations and clinical implications	Jérôme Abadie, Nantes
12:30-13:00	Panel discussion: Reporting resection margins, histologic grades and proliferation markers – implications for postop decision making	all speakers
13:00-14:15	Lunch on your own
	General abstracts
14:15-14:27	Clinicopathologic characteristics, postoperative outcome and prognostic factors in 61 dogs with primary pulmonary carcinomas	dr. Tanja Plavec
14:27-14:39	Lymphoma risk by clade and age of diagnosis as potential markers of genetic risk in dogs.	dr. Peter Bennett
14:40-15:00	Announcement presentations for World Veterinary Cancer Conference 2020 Tokyo & ESVONC 2020 Syracusa
15:01-15:13	Opportunities and challenges of active immunotherapy in dogs with B-cell lymphoma: a 5-year experience in two veterinary oncology centers	dr. Laura Marconato
15:13-15:25	Canine splenic masses: a systematic review of the literature for possible pre-surgical determinants of malignancy and creation of a new grading system	dr. Valerie J. Poirier
15:25-15:37	USP7 inhibitor as a novel drug candidate for canine lymphoma/leukemia treatment	dr. Aleksandra Pawlak
15:37-15:49	A novel aggressive T-cell lymphoma/leukemia in young dogs	dr. Paul Avery
15:49-16:01	Canine multicentric lymphoma (CML): towards a European consensus for diagnostic imaging ?	dr. Catherine Ibisch
16:01-16:13	Refining the double two-thirds rule: the importance of breed and clinical presentation to predict the diagnosis of canine splenic mass lesions in 288 dogs	dr. Owen Davies
*16:15-16:30*	*Farewell ceremony*